CTOs on the Move

Epic Pharmacy Network

www.epicrx.com

 
Formed in 1982 and headquartered in Maryland, EPIC Pharmacies is a not-for-profit buying group of hundreds of independently owned pharmacies across the country. EPIC offers a full range of programs and services while returning its net revenues to its members throughout the year, including a year-end distribution.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.epicrx.com
  • 5024 Campbell Boulevard Suite R
    Nottingham, MD USA 21236
  • Phone: 804.379.9060

Executives

Name Title Contact Details
Luke Gordon
Vice President of Network Development Profile

Similar Companies

Integrated Nano-Technologies

Integrated Nano-Technologies is a Henrietta, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rx Biotech Specialty Pharmacy

Rx Biotech Specialty Pharmacy is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Butterfield's Pharmacy and Medical Supplies

Butterfield's Pharmacy and Medical Supplies is a Fort Pierce, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Prometheus Laboratories

Prometheus Laboratories Inc. is one of the leading companies in the Healthcare, Pharmaceuticals and Biotech sector.

Corcept Therapeutics

Corcept Therapeutics Incorporated, a pharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of metabolic, oncologic, and psychiatric disorders in the United States. The company focuses on disorders that are associated with a steroid hormone called cortisol. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing Korlym’s active ingredient, which is in a Phase 1/2 trial in combination with the chemotherapy drug eribulin (Halaven) to treat patients with GR-positive triple-negative breast cancer, a form of cancer with a particularly poor prognosis; and CORT 125134, a proprietary, selective GR antagonist that is in a Phase 1 clinical study to assess its safety, tolerability, and pharmacokinetics in healthy human volunteers. In addition, it discovers and develops three series of novel selective GR-II antagonists. The company has research and development agreements with Argenta Discovery Limited and Sygnature Discovery Limited. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.